ETOP IBCSG Partners Foundation

CHOSA's Platinum Drug Response Predictor Shows Promise in Personalizing Cancer Treatment

- CHOSA will release results from a blinded retrospective study predicting cisplatin efficacy in lung cancer patients from the SPLENDOUR trial by the end of Q2 2025, potentially revolutionizing treatment selection. - The company's Drug Response Predictor (DRP) for platinum drugs demonstrated significant clinical value in breast cancer, where a 50% difference in DRP score corresponded to a three-fold difference in carboplatin treatment benefit. - CHOSA's predictive technology could enhance the efficacy of platinum-based therapies across multiple cancer types and improve outcomes when combined with immunotherapy, addressing a critical need in the $60 billion PD-1/PD-L1 market.